Verdenelli Maria Cristina, Ghelfi Francesca, Silvi Stefania, Orpianesi Carla, Cecchini Cinzia, Cresci Alberto
Dipartimento di Scienze Morfologiche e Biochimiche Comparate, Università di Camerino, Camerino, Italy.
Eur J Nutr. 2009 Sep;48(6):355-63. doi: 10.1007/s00394-009-0021-2. Epub 2009 Apr 14.
The possibility of using microbes to maintain health, and to prevent or treat disease is a topic as old as microbiology. The research of novel probiotic strains is important in order to satisfy the increasing request of the market and to obtain functional products in which the probiotic cultures are more active and with better probiotic characteristics than those already present on the market.
In this study, the probiotic potential of Lactobacillus strains isolated from Italian elderly human faeces was investigated.
The Lactobacillus strains were identified and examined for resistance to gastric acidity and bile toxicity, adhesion to HT-29 cells, antimicrobial activities, antibiotic susceptibility and plasmid profile. Survival of the strains through human intestine was examined in a 3 months human feeding trial.
Two strains, Lactobacillus rhamnosus IMC 501 and Lactobacillus paracasei IMC 502, tolerated well low pH and bile acids. In antimicrobial activity assays, both strains showed inhibitory properties towards selected potential harmful microorganisms, particularly against Candida albicans. The two selected strains expressed high in vitro adherence to HT-29 cells increasing this characteristic when they are used in combination and they were resistant to vamcomycin, colistin sulphate, gentamicin, oxolinic acid and kanamycin. Moreover, the two strains could be recovered from stools of volunteers after the feeding trials.
Lactobacillus rhamnosus IMC 501 and L. paracasei IMC 502 present favourable strain-specific properties for their utilisation as probiotics in functional foods and the high adhesion ability of the L. rhamnosus IMC 501 and L. paracasei IMC 502 used in combination, confirmed by both in vitro and in vivo study, indicate that the two bacterial strains could be used as health-promoting bacteria.
利用微生物来维持健康、预防或治疗疾病的可能性是一个与微生物学一样古老的话题。为了满足市场日益增长的需求,并获得功能性产品,其中益生菌培养物比市场上现有的更具活性且具有更好的益生菌特性,新型益生菌菌株的研究很重要。
本研究调查了从意大利老年人粪便中分离出的乳酸杆菌菌株的益生菌潜力。
对乳酸杆菌菌株进行鉴定,并检测其对胃酸和胆汁毒性的抗性、对HT - 29细胞的粘附性、抗菌活性、抗生素敏感性和质粒图谱。在为期3个月的人体喂养试验中检测菌株在人体肠道中的存活情况。
两株菌株,鼠李糖乳杆菌IMC 501和副干酪乳杆菌IMC 502,对低pH值和胆汁酸耐受性良好。在抗菌活性测定中,两株菌株对选定的潜在有害微生物均表现出抑制特性,特别是对白色念珠菌。所选的两株菌株在体外对HT - 29细胞表现出高粘附性,当它们联合使用时这种特性增强,并且它们对万古霉素、硫酸多粘菌素、庆大霉素、恶喹酸和卡那霉素具有抗性。此外,在喂养试验后,可从志愿者的粪便中回收这两株菌株。
鼠李糖乳杆菌IMC 501和副干酪乳杆菌IMC 502具有作为功能性食品益生菌的良好菌株特异性特性,体外和体内研究均证实,鼠李糖乳杆菌IMC 501和副干酪乳杆菌IMC 502联合使用时具有高粘附能力,表明这两种细菌菌株可作为促进健康的细菌。